Chloe Diamond

Chloe Diamond assists life sciences clients in the design and launch of strategic communications, marketing, and customer engagement platforms to help them engage with key audiences.

With experience in healthcare communications and public health education, she provides strategic insight and campaign support to clients.

Prior to joining Avalere, Chloe worked in the Social Marketing practice at Ketchum Public Relations where she conducted media monitoring and research, supported a webinar series on value-based and quality care, and contributed to the development of public-facing resources to educate the public on Centers for Medicare and Medicaid Services programs. While in graduate school, she completed internships at the Patient-Centered Outcomes Research Institute, FasterCures: A Center of the Milken Institute, the Food Research and Action Center, and the FDA.

Chloe has an MPH in public health communication and marketing from The George Washington University and a BS in nutrition with a minor in English from Arizona State University.

Authored Content

Mental Health Awareness Month and the COVID-19 crisis intersect—and highlight challenges in the US mental health care system

To protect the public’s health during the COVID-19 pandemic, the Food & Drug Administration (FDA) released guidance expanding the availability of digital health therapeutic devices and applications for psychiatric disorders by clarifying which regulatory requirements it does not plan on enforcing as well as which products do not necessitate FDA oversight. This guidance intends to limit extraneous contact between patients (users) and providers by providing regulatory flexibility for low risk products. The policies will last until the national public health emergency ends.

Beginning in 2019, CMS will reimburse for 5 codes relating to virtual care delivery and remote monitoring